Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) just unveiled an announcement.
JCR Pharmaceuticals reported a sharp turnaround in earnings for the nine months ended December 31, 2025, with net sales rising 17.3% year on year to ¥30.35 billion and a swing to profit attributable to owners of parent of ¥1.74 billion from a loss a year earlier, lifting basic earnings per share to ¥14.30. While total assets increased to ¥113.3 billion, the equity ratio weakened slightly to 40.8%, and the company kept its dividend plan intact at an annual ¥20 per share. Management also raised full-year FY2025 guidance, now forecasting net sales of ¥39.5 billion and profit attributable to owners of parent of ¥1.6 billion, signaling confidence in the earnings recovery and improved operational momentum, which is likely to be closely watched by investors following last year’s losses.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen705.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange that develops and manufactures therapeutic products, with a focus on specialty and biopharmaceuticals. The company operates in prescription drug markets and related healthcare fields, targeting both domestic and international demand for advanced treatments.
Average Trading Volume: 975,166
Technical Sentiment Signal: Hold
Current Market Cap: Yen83.9B
For detailed information about 4552 stock, go to TipRanks’ Stock Analysis page.